becton dickinson compani
feb pm et
summari compani provid wide rang medic devic diagnost product use
hospit doctor offic research lab set
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
expect fy sep sale inclus
bard bcr rise follow
declin fy account
divestitur respiratori solut unit
report three busi
segment medic life scienc
intervent see oper margin
fy fy
lead medic devic compani focus
vascular urolog oncolog market
share consist cash
share bcr share
total enterpris valu combin
compani sale
lead global presenc sale
oversea includ china
march acquir carefus
cfn lead provid medic
devic diagnost product hospit
physician incorpor
bd medic unit bd life scienc
unit remain unchang
fy ep estim
view bcr deal posit see bcr
acceler sale growth expand
margin believ deal
immedi accret earn
gener high-single-digit accret fy
sep also see million
cost synergi fy addit
compani sizeabl presenc china
among fastest grow market
howev note deal increas
leverag ebitda
plan de-lev within three
year separ encourag
strong global demand safeti
diabet care diseas test product
sustain long term
intern sale account sale
look sale china account
intern sale continu
improv strengthen fy
risk opinion target price includ
slower-than-expect recoveri key life
scienc market continu cutback
spend compani hospit
custom prolong soft
target price line
peer fy ep estim
market competit new product
introduct competitor potenti
significantli affect market dynam chang
domest foreign health care industri practic
regul may result increas price pressur
lower reimburs product still
product line favor demand price
characterist medic equip
industri gener
may ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
becton dickinson compani
becton dickinson compani trace root concern start maxwel becton fairleigh
dickinson one first compani sell -made glass syring also pioneer
product hypoderm needl compani manufactur sell medic suppli
devic lab equip diagnost product use health care institut life scienc research
clinic laboratori industri gener public
major product core medic system divis includ hypoderm syring needl inject
insulin syring pen needl diabet care infus therapi devic prefil drug deliveri
system surgic blade scalpel segment also market specialti blade cannula
ophthalm surgeri procedur anesthesia needl critic care system elast support product
diagnost segment provid rang product design safe collect transport
diagnost specimen instrument analysi across wide rang infecti diseas test
includ health care-associ infect hai princip product servic includ integr
system specimen collect extens line safety-engin blood collect product
system plate media autom blood cultur system molecular test system sexual
transmit diseas hai microorgan identif drug suscept system liquid-bas
cytolog system cervic cancer screen rapid diagnost assay segment also includ
consult servic custom autom bar-cod system patient identif
bioscienc unit provid research tool reagent clinician medic research studi
gene protein cell order better understand diseas improv diagnosi diseas
manag facilit discoveri develop novel therapeut product includ
instrument system cell sort analysi monoclon antibodi reagent kit diagnost
research use tool aid drug discoveri vaccin develop molecular biolog product fluid
handl cell growth screen product
march acquir carefus cfn billion share consist cash
share cfn share cfn lead provid medic devic diagnost
product hospit physician
august acquir sirigen group ltd develop polym dye use flow cytometri
august acquir carmel pharma ab swedish compani manufactur phaseal
lead closed-system drug transfer devic safe handl hazard drug
packag vial acquisit expand scope health care worker safeti emphasi
develop manufactur person flow cytomet research
decemb compani acquir remain stake tripath imag inc
alreadi per share cash million tripath sell product use diagnos cancer
emerg molecular oncolog busi also took in-process charg
million associ three project molecular pap test use proprietari molecular biomark
reagent intend allow primari screen cervic cancer breast stage use
proprietari molecular biomark reagent intend predict risk diseas recurr
aid treatment select patient earli stage breast cancer ovarian cancer detect
intend allow serum-bas screen monitor assay ovarian cancer base upon
detect multipl biomark use proprietari panel biomark assay algorithm
april compani open second manufactur facil suzhou china new bd
diagnost facil produc rapid diagnost product flu viral infect initi focu
influenza respiratori syncyti viru time becton expect expand rang diseas
product diagnos includ addit bacteri parasit viral diseas product made
plant sold global market includ asia europ latin america north america
august complet sale ophthalm system unit surgic blade critic
care extend dwell cathet product platform asset gener approxim million
annual revenu octob compani sold discoveri labwar unit exclud advanc
bioprocess platform corn inc million labwar unit annual sale
senior vice-president corpor
execut vice-president global
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
fundament outlook health care
equip sub-industri next month
neutral continu view mani product
categori histor recession-resist
expect continu grow albeit
slowli growth procedur rate
slow area normal view
non-elect cardiac rhythm
manag intervent cardiolog
orthoped recent howev equip
maker think certain procedur rate may
stabil start recov
medic devic tax requir
healthcar reform law went effect
januari temporarili
suspend
elect donald trump republican
retain control congress believ
gop abil substanti alter
afford act includ potenti
elimin variou health care sector fee
tax although gop replac
remain uncertain believ
potenti fewer insur patient
neg impact equip sub-industri
fewer insur patient would like lead
fewer procedur anticip
hospit largest buyer
medic equip would also advers
impact could pressur
expect revenu rise constant
currenc mid- upper-singl digit pace
aid new product expans emerg
market case acquisit
still expect extend replac cycl
 hospit area price
demand certain product categori
unfavor foreign exchang continu
hospit becom cautiou regard
base index
five-year market price perform feb
capit budget amid shift
procedur inpati outpati
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
sub-index increas vs rise
 composit index follow
rise health equip
index vs declin
composit index year date
juli health
equip index rose vs rise
 composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
becton dickinson compani announc retir ellen strahlman
execut vice presid research develop chief medic offic
compani rais target price
in-lin peer forward ep estim jun-q
ep vs in-lin ahead estim rais fy
sep ep estim sale divestitur
respiratori solut unit fell pro forma basi sale rose
bd medic sale pro forma basi rose bd life scienc rose
pend acquisit cr bard track close fourth
quarter calendar year see deal acceler sale margin
et cfra rais opinion share becton dickinson buy
hold agre buy cr bard bcr
lead devic firm vascular urolog oncolog share
consist cash share bcr share
combin compani lead global presenc medic
manag infect prevent vascular surgic specialti
sale includ china view deal posit
see bcr acceler sale expand margin rais
target slightli peer ep estim
/jeffrey loo cfa
becton dickinson compani announc appoint tom polen
presid effect immedi new role mr polen overse
bd oper segment medic life scienc segment
well new intervent segment includ bard inc
busi follow close bd acquisit bard mr polen
current execut vice presid presid bd medic segment
continu report vinc forlenza remain chairman ceo
analyst research note compani news
compani rais target price
line peer fy sep ep estim
inclus bard set fy dec-q ep vs
ahead estim sale rose bd medic
bd life scienc robust diagnost system sale aid
earlier flu season expect robust sale emerg market
china continu fy look integr
bard lift gross margin bp oper margin bp
becton dickinson compani held jan approv
retir basil anderson jim orr board compani also
announc appoint mike overlock board director dave melcher
tim ring also join board follow servic director
set fy sept ep estim
account pend acquisit cr bard bcr
pend divestitur soft tissu core needl biopsi product line
bcr aspira product line expect bcr
acquisit relat divestitur complet shortli reiter
forecast bcr deal acceler sale margin
updat model upon deal complet keep target price
in-lin peer fy ep estim /jeffrey
compani rais target in-lin
peer fy sept ep estim sept-
ep estim sale account
divestitur respiratori solut fell pro forma basi sale rose
bd medic pro forma sale rose bd life scienc rose
stand-alon basi see fy sept sale growth
ep pend acquisit cr bard bcr
track close fourth quarter calendar /jeffrey loo cfa
bd becton dickinson compani announc two current director
 bard inc join bd board director follow complet
bd pend acquisit bard timothi ring chairman ceo bard
david melcher presid ceo aerospac industri
associ elect two newli creat seat bd board
director accord acquisit agreement mr ring serv
chairman ceo bard sinc aug join bard june
serv mani leadership role includ corpor vice presid
human resourc group vice presid group presid
coronari vascular product group presid electrophysiolog
peripher vascular product prior join bard mr ring work
gener motor corpor addit
bard board director mr ring director
incorpor truste new jersey health foundat njhf
board member advanc medic technolog associ advam
nation associ manufactur nam healthcar leadership
council also current serv cornel univers council
former chairman board truste healthcar institut new
jersey hinj david melcher presid ceo aerospac
industri associ sinc prior mr melcher ceo
presid exe inc addit director bard mr
melcher member feder aviat administr nextgen advisori
committe provid advic policy-level issu nation aviat
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
